CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma [0.03%]
CD4⁺T细胞通过协调免疫反应来对抗ALK阳性T细胞淋巴瘤
Teresa Poggio,Linda Gräßel,Geoffroy Andrieux et al.
Teresa Poggio et al.
Immunotherapy has revolutionized the treatment of solid cancers in recent years. However, T-cell lymphomas (T-NHLs) originate from immune cells themselves and are biologically heterogeneous, rendering investigations of immune checkpoint inh...
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004 [0.03%]
lisocabtagene maraleucel联合伊布替尼治疗复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤：TRANSCEND CLL 004研究主要结果分析
William G Wierda,Kathleen A Dorritie,Jordan Gauthier et al.
William G Wierda et al.
Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1...
Human HSPCs clones balance stochastic diversification with cytokine-induced differentiation [0.03%]
人HSPC克隆体通过随机分化与细胞因子诱导的分化之间取得平衡
Elia Colin,Dror Brook,Jonathan Izraeli et al.
Elia Colin et al.
Hematopoietic stem and progenitor cells (HSPCs) balance self-renewal with on-demand differentiation of blood lineages. Modern bone marrow atlases specify static transcriptional states, but not HSPC dynamics, which are only partly understood...
Erythroblast-derived lipid mediators program neutrophil development and function [0.03%]
红细胞衍生的脂质介质编程中性粒细胞的发育和功能
Duco Steven Koenis,Roberta De Matteis,Esteban Alberto Gomez Cifuentes et al.
Duco Steven Koenis et al.
Granulopoiesis is a tightly regulated process encompassing the production, maturation, and release of neutrophils in the bone marrow, ensuring their optimal physiological contribution to host defence. The mechanisms that maintain a balanced...
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML [0.03%]
OPTI-AML：评估维奈克拉联合阿扎胞苷诱导治疗14天和28天在老年急性髓系白血病（AML）患者中的疗效的前瞻性研究
Uma M Borate,Ying Huang,Tara L Lin et al.
Uma M Borate et al.
Azacitidine (Aza) plus venetoclax (Ven) is standard treatment for older/unfit patients with newly diagnosed (ND) acute myeloid leukemia (AML). The approved 28-day (D) Ven schedule is associated with prolonged cytopenias, causing frequent do...
BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia [0.03%]
靶向BCMA的CAR-T细胞治疗难治性原发免疫性血小板减少症取得持久无药缓解
Jinhui Shu,Min Xu,Peiru Li et al.
Jinhui Shu et al.
This first clinical evaluation of BCMA CAR-T cell therapy in four patients with refractory primary ITP demonstrated manageable safety, rapid and sustained platelet recovery, and durable drug-free complete remission lasting up to 15 months, ...
MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma [0.03%]
MRD动力学预测了进展并揭示了多发性骨髓瘤免疫治疗拦截的脆弱状态
Carmen Gonzalez,Camila Guerrero,Marta Larrayoz et al.
Carmen Gonzalez et al.
The clinical significance of one or two measurable residual disease (MRD) assessments is established in multiple myeloma (MM). However, how to stratify patients according to ≥3 MRD assessments remains unknown. The traits of MRD resistance ...
Factor V is an anticoagulant of the extrinsic pathway of coagulation and modifier of thrombin generation in hemophilia A [0.03%]
因子V是凝血外源途径的抗凝物质，在甲型血友病中可调节凝血酶生成
Megan Jewell,Christine H Baird,Dianne Thornhill et al.
Megan Jewell et al.
Factor V (FV) links procoagulant amplification to anticoagulant feedback, but how FV limits tissue factor-initiated coagulation are not fully defined. We hypothesized that procofactor FV downregulates factor X (FX) activation by tissue fact...
Sophie Paczesny
Sophie Paczesny
Peisong Ma
Peisong Ma